Danish pharmaceutical company Novo Nordisk plans to invest DKK 500m in expanding the company's production facilities near Copenhagen in Denmark, informs the company in a press release Thursday morning.
According to the company, this is to ensure the company's production capacity for the diabetes drug Rybelsus, which is based on the molecule semaglutide.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.